Robotics to Be the Driving Force Behind J & amp;J ’s Device Unit
Johnson & Johnson is offering a preview of its surgical robotics strategy  May 13th during its Medical Device Business Review Day in New York. Executives of the New Brunswick, NJ-based company announced the date during a call discussing its 4Q19 results on Wednesday.
Alex Gorsky, J&Jâs CEO noted that going forward surgical robotics would be a driving force behind the companyâs medtech division.
âAs it relates to medical devices, we've been, I think, very consistent in sharing our thinking that, again, this next generation is certainly about the robotics component that helps facilitate perhaps having more consistency in an exact procedure, perhaps getting into a tighter space, having better access,â Gorsky said, according to a Seeking Alpha transcript of the earnings call.
The news follows the healthcare giant buying out Verilyâs interest in the Verb Surgical joint venture for an undisclosed sum. The Verb buyout is one of two major developments that occurred last year that are set to power J&Jâs upcoming surgical robotics platform. The second development is J&Jâs acquisition of Auris Health.
Redwood City, CA-based Auris Health develops robotic technologies that have been focused on lung cancer. The firm has the Monarch Platform, an FDA-cleared system currently used in bronchoscopic diagnostic and therapeutic proce...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Digital Health Source Type: news
More News: Bronchoscopy | Cancer | Cancer & Oncology | Lung Cancer | Lung Transplant | Medical Devices | Mergers and Aquisitions | Orthopaedics | Partnerships